

Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia

Friday, December 6, 2019

1:00 PM – 3:30 PM

Orlando, Florida

Moderator

Neil Love, MD

Faculty

Jeremy Abramson, MD

Bruce D Cheson, MD

Prof John G Gribben, MD, DSc, FMedSci

Brad S Kahl, MD

Loretta Nastoupil, MD

Laurie H Sehn, MD, MPH

Disclosures for Moderator Neil Love, MD

Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

Agenda

Module 1 – Dr Kahl: *Evolving Therapeutic Algorithms for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL)*

Module 2 – Prof Gribben: *Management of Relapsed/Refractory (R/R) CLL and Novel Investigational Approaches*

Module 3 – Dr Cheson: *Contemporary Management of Newly Diagnosed and R/R Follicular Lymphoma (FL)*

Module 4 – Dr Abramson: *Protocol and Off-Protocol Care for Patients with Mantle Cell Lymphoma (MCL)*

Module 5 – Dr Sehn: *Recent Breakthroughs and Other Promising Approaches in the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)*

Module 6 – Dr Nastoupil: *Integration of CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Lymphomas*

ASH Working Group Participants



Warren S Brenner, MD
Boca Raton, Florida



Gautam Kale, MD, MS
Greensboro, North Carolina



Khuda Dad Khan, MD, PhD
Louisville, Kentucky



Zanetta S Lamar, MD
Naples, Florida



Neil Morganstein, MD
Summit, New Jersey



Namrata I Peswani, MD
Orland Park, Illinois